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Unbiased shRNA library screens revealed that the estrogen re-
ceptor-1 (ESR-1) is a key factor regulating HIV-1 latency. In both
Jurkat T cells and a Th17 primary cell model for HIV-1 latency,
selective estrogen receptor modulators (SERMs, i.e., fulvestrant,
raloxifene, and tamoxifen) are weak proviral activators and sensi-
tize cells to latency-reversing agents (LRAs) including low doses of
TNF-α (an NF-κB inducer), the histone deacetylase inhibitor vorino-
stat (soruberoylanilide hydroxamic acid, SAHA), and IL-15. To
probe the physiologic relevance of these observations, leukaphe-
resis samples from a cohort of 12 well-matched reproductive-age
women and men on fully suppressive antiretroviral therapy were
evaluated by an assay measuring the production of spliced enve-
lope (env) mRNA (the EDITS assay) by next-generation sequencing.
The cells were activated by T cell receptor (TCR) stimulation, IL-15,
or SAHA in the presence of either β-estradiol or an SERM.
β-Estradiol potently inhibited TCR activation of HIV-1 transcription,
while SERMs enhanced the activity of most LRAs. Although both
sexes responded to SERMs and β-estradiol, females showed much
higher levels of inhibition in response to the hormone and higher
reactivity in response to ESR-1 modulators than males. Impor-
tantly, the total inducible RNA reservoir, as measured by the EDITS
assay, was significantly smaller in the women than in the men. We
conclude that concurrent exposure to estrogen is likely to limit the
efficacy of viral emergence from latency and that ESR-1 is a phar-
macologically attractive target that can be exploited in the design
of therapeutic strategies for latency reversal.
HIV-1 latency | HIV-1 reservoir | estrogen receptor | latency-reversing
agents | selective estrogen receptor modulators
Patients adhering to combination antiretroviral therapy (ART)regimens have minimal plasma viremia, but unfortunately
HIV-1 still persists due to the existence of a tiny population of
transcriptionally silent viruses (1–3) that reside primarily in
memory CD4+ T cells in the peripheral blood (4) and tissues (5).
Latently infected T cells are already established during the acute
phase of infection when viremia is highest, and early initiation of
ART cannot prevent the seeding of this pool of latently infected
cells (6). The latent reservoir is very stable, with an apparent half-
life of 44 mo in the presence of ART (7, 8). Recent studies of
proviral integration sites have provided strong evidence for clonal
expansion of specific proviruses, suggesting that the reservoirs can
be replenished through homeostatic proliferation (9, 10).
Devising strategies that safely and effectively eradicate the
latent reservoir is the challenging goal of current HIV-1 “cure”
efforts (11, 12). In quiescent T cells, latency is maintained
through restrictions imposed on both the cellular transcription
machinery, due to sequestration of the transcriptional elongation
factor P-TEFb and the transcriptional initiation factors including
NF-κB and NF-AT and the imposition of epigenetic silencing by
histone methyltransferases (13). These complementary restric-
tions make it difficult to reverse proviral latency with single
agents (14). Clinical studies examining candidate latency-reversal
agents (LRAs) have demonstrated transient increases in cell-
associated HIV-1 RNA, but none of these agents has led to a
significant change in integrated HIV-1 DNA or the inducible
reservoir (15).
Using an unbiased, genome-wide shRNA screen to identify
pathways relevant to latency, we identified estrogen receptor-1
(ESR-1) as a cellular factor critical for the maintenance of HIV-
1 latency. Although earlier reports suggested that estrogen can
inhibit HIV-1 transcription (16, 17) in activated cells, the asso-
ciation of ESR-1 with latency control was unexpected and may
underlie the observation that plasma HIV RNA levels tend to be
lower in women than men (18).
Our group established a cohort of 52 well-matched reproductive-
age women and men with comparable clinical and demographic
features. Using a subset of women and men from this cohort who
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underwent leukapheresis, we showed that latent proviruses can be
partially reactivated in both sexes in response to selective estrogen
receptor modulators (SERMs) and potently inhibited by hormone
exposure. Females showed significantly higher levels of inhibition in
response to β-estradiol and higher reactivity in response to SERMs
than males and had larger inducible RNA reservoirs. These data
demonstrate physiologically determined differences in the behavior
of the proviral reservoirs in women and men, highlighting the need
to design cure-related clinical studies and therapeutic regimens that
effectively target both sexes (19).
Results
ESR-1 Regulates HIV-1 Latency. An unbiased genome-wide shRNA
screen for cellular factors required for the maintenance of HIV-
1 latency demonstrated that ESR-1 is one of the key factors reg-
ulating latency. As shown in Fig. 1 A and B, a synthetic lentiviral
Fig. 1. ESR-1 is required to maintain HIV-1 latency. (A) Repressor screen. Latently infected Jurkat 2D10 cells (d2EGFP reporter) were infected with a shRNA
library (RFP reporter). GFP+, RFP+ cells were purified by three sequential rounds of sorting. (B) Activator screen. Cells were stimulated with TNF-α before
sorting for d2EGFP−, RFP+ cells. After each round of sorting, genomic DNA was isolated, and shRNAs were identified by nested PCR amplification with
barcode-specific primers followed by Illumina sequencing. (C) Ratio between normalized abundance values of shRNAs from the repressor screen (d2EGFP+)
and activator screen (d2EGFP−) candidates. Data are from the module 1 screen (14,849 shRNAs identified). (D) The level of enrichment of ESR-1 and a
number of additional genes with known roles in HIV latency is shown for three repressor screen datasets from two different rounds of selection (sorts
2 and 3) and two independent experiments. The initial level of representation of each gene in the transfected cell population (sort 0) and the results of
two activator screen datasets performed after stimulation with either 1 ng or 6 ng/mL of TNF-α are shown as controls. The level of enrichment of each
gene is the number of RNA-seq reads mapped to the gene per million total mapped reads, flattened to a maximum enrichment value of 6,000 reads per
million.
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shRNA library from Cellecta, Inc. containing 82,500 shRNAs
targeting 15,439 mRNA sequences in three modules was used to
infect 2D10 cells, which are a latently infected Jurkat T cell line
(20–22). Cells carrying reactivated proviruses (repressor screen) or
cells that failed to reactivate after stimulation by TNF-α (activator
screen) were then purified by sequential rounds of sorting. This
resulted in a progressive enrichment for clones expressing
shRNAs that either led to constitutive reactivation of HIV-1 or
blocked HIV-1 reactivation by TNF-α (SI Appendix, Fig. S1A).
Analysis of the shRNA repressor screen data obtained from
next-generation sequencing (NGS) of samples from three se-
quential rounds of enrichment was performed using edgeR (23).
To help identify and eliminate genes that were enriched due to
their impact on cell growth and other confounding factors in cell-
based screens, the ratio of the normalized abundance values of
shRNAs identified by the two opposing selection conditions was
calculated (Fig. 1C). The results from all shRNAs targeting the
same gene (three to six per gene) were summarized to obtain
gene-level enrichment data per replicate group. False-discovery
rates (FDRs) and P values were calculated from the enrichment
values obtained from the repressor–activator screen comparison.
ESR-1 was the second most enriched gene in the repressor
screen, with enrichment levels ranging between eightfold after
the first round of sorting (FDR = 0.008) to 40-fold after the
second round of sorting and 550-fold after the third round of
sorting (FDR = 9E-05–2E-05) (Fig. 1 C and D).
Bee swarm plots were also used to illustrate the high level of
enrichment of ESR-1 achieved for three independent repressor
screen datasets from two different rounds of selection (dataset 1,
sorts 2 and 3) and two independent experiments (dataset 2, sort
2) (Fig. 1D). By contrast, there was no significant enrichment of
ESR-1 in the unsorted cell population or in two independent
activator screens performed with TNF-α.
A number of previously identified HIV-1 latency factors
served to validate the procedure (Fig. 1D). In particular, BRD4,
which competes for Tat and is the key target of the LRA JQ1
(24), was reproducibly highly ranked in the repressor screen and
is known to induce latent HIV after shRNA knockdown (25).
To confirm ESR-1 as a hit, knockdown of the ESR-1 transcript
by the specific shRNA sequence from the screening library was
performed. Successive rounds of sorting led to the isolation of a
constitutively reactivated proviral population (93.08%) com-
pared with 2.84% reactivation using a scrambled shRNA control
(SI Appendix, Fig. S1B). Since HIV-1 induction in Jurkat cells is
exquisitely sensitive to the activation of NF-κB, an important
control to demonstrate the specificity of the ESR-1 shRNA
knockdowns was to rule out induction of NF-κB–p65 in the
shRNA-treated cells. Flow cytometry-based image-stream anal-
ysis (SI Appendix, Fig. S1C) and immunoblot analysis of nuclear
extracts (SI Appendix, Fig. S1D) showed no nuclear localization
of NF-κB–p65 in either scrambled shRNA or ESR-1 shRNA-
knockdown cells.
In addition to ESR-1 itself, the shRNA screen identified a
number of interacting proteins that also ranked highly in the re-
pressor screen. A GeneMANIA-generated network (SI Appendix,
Fig. S2A) identified several molecules that ranked at the top of the
screening list which also are known to directly modulate or in-
fluence the biological activity of ESR-1, including the nuclear
receptor coactivators 1 and 3 (NCOA1 and 3). Heat maps from an
independent analysis of the ESR-1 interactome using the list of
ESR-1–containing complexes in the CORUM (26) and PCDq
databases (27) and Gene Ontology (GO) terms related to estro-
gen signaling similarly indicated the enrichment of ESR-1–
interacting proteins in the shRNA screen (SI Appendix, Fig. S3).
Pharmacological Control of HIV Latency in Primary Cells Using ESR-1
Antagonists and Agonists. The quiescent effector cell latency
(QUECEL) model (Fig. 2) is a robust primary cell model for
HIV latency (20, 28) using polarized effector memory T cell
populations (29, 30). Briefly, naive helper T cells were polarized
to a Th17 polarization phenotype, which represents the most
abundant effector T cell population in the lamina propria of the
gastrointestinal tract and a major reservoir for HIV (31, 32).
Peripheral blood mononuclear cell (PBMC) populations with the
highest frequency of HIV-1 proviruses are detected in Th1 cells,
followed closely by Th17 cells (33).
The expanding polarized T cells were infected using a single-
round reporter virus carrying the tat, rev, env, and nef genes (21,
22) and a CD8a–EGFP fusion protein that permitted the puri-
fication of infected cells with magnetic beads (Fig. 2A). The
HIV-1–infected cells are forced into quiescence by culturing the
cells in restrictive cytokine medium (low IL-2 and IL-23) sup-
plemented with the antiinflammatory cytokines IL8, IL-10, and
TGF-β (Fig. 2B). The quiescent cells were in the Go phase of the
cell cycle, showed negligible 5-ethynyl-2′-deoxyuridine (EDU)
incorporation, and were negative for Ki67 and cyclin D3 (SI
Appendix, Fig. S4A).
Once the cells become quiescent, the level of HIV-1 Nef pro-
tein is reduced to almost undetectable levels (<1.5%), indicative
of HIV-1 latency (Fig. 2C and SI Appendix, Fig. S4B), but a
moderate level of GFP persists in the quiescent cells because of
the high stability of the CD8a–GFP fusion protein, which serves as
a marker of infection (SI Appendix, Fig. S4B). Stimulation through
the T cell receptor (TCR) by α-CD3/α-CD28 Dynal magnetic
beads, induced Nef and cycling markers dramatically (>79%) (SI
Appendix, Fig. S4). We therefore routinely use Nef, rather than
CD8a–GFP, as a marker of proviral transcription. Since LRAs do
not always force the cells into proliferation, we use a P-TEFb–
specific marker, pSer175 CDK9, to identify cells that have be-
come activated (SI Appendix, Fig. S4B) (25, 34). Accordingly, in
the QUECEL assays presented here, we have scored Nef and
pSer175 doubly positive cells (Fig. 2).
The extensive armamentarium of therapeutically developed
ESR-1 modulators provides informative tools to study the role of
ESR-1 in the repression of HIV-1 transcription in the QUECEL
(Th17) model (Fig. 2 and SI Appendix, Fig. S5) and Jurkat T cells
(SI Appendix, Fig. S2). In both systems, ESR-1 agonists are po-
tent repressors of HIV proviral reactivation, while ESR-
1 antagonists (SERMS) are weak activators by themselves and
potentiate activation by other LRAs, such as the histone deace-
tylase inhibitor (HDACi) vorinostat (soruberoylanilide hydroxa-
mic acid, SAHA), TNF-α, and IL-15.
Ordinary tissue-culture media containing FBS can be a source
of β-estradiol, and phenol red is an estrogen analog. To control
for this in our ex vivo experiments, we used medium without
phenol red and charcoal-stripped FBS. The levels of β-estradiol
were measured in all media using a sensitive ELISA (SI Ap-
pendix, Fig. S6). All media used in these studies contained less
than 10 pg/mL β-estradiol, which is at the level of detection for
the assay. We also used the ELISA to confirm the accuracy of
the added β-estradiol levels.
The impact of a wide range of ESR-1 agonists and SERMs
(antagonists) were tested in the Th17 model using cells from three
separate donors, two male and one female (Fig. 2 and SI Ap-
pendix, Fig. S5). β-Estradiol and the ESR-1 synthetic agonist
diethylstilbestrol (DES) were extremely potent blockers of TCR-
mediated proviral reactivation, and both compounds partially
blocked viral induction by SAHA, TNF-α, and IL-15 (Fig. 2C).
The ESR-1 antagonists tamoxifen (TMX) and fulvestrant (ICI)
had the opposite effect, partially reactivating latent HIV-1, with
additive effects on proviral reactivation when combined with ei-
ther SAHA or IL-15 (Fig. 2 and SI Appendix, Fig. S5). For ex-
ample, treatment of the quiescent Th17 cells with 1 μM TMX or
500 nM SAHA activated 21.29% and 22.56% of the cells, re-
spectively, whereas the combination of TMX and SAHA activated
51.25% of the cells (Fig. 2D).
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The NCOA1 and NCOA3 inhibitor gossypol, an agent under
investigation as a male oral contraceptive (35), partially reac-
tivated the latent proviruses as a solo agent and sensitized cells to
reactivation by SAHA, TNF-α, and IL-15 (Fig. 2D and SI Ap-
pendix, Fig. S5C).
Calculation of Bliss scores showed potent repression of HIV
transcription by the ESR-1 agonists (Fig. 2E) and additive or
occasionally (depending on the donor) synergistic effects of
ESR-1 antagonists on proviral reactivation with SAHA, TNF-α,
and IL-15 (Fig. 2F). Titrations of the SERMs ICI and TMX in
the presence and absence of SAHA confirmed the additive ef-
fects of these agents (SI Appendix, Fig. S5D).
ESR-1 Accumulates on the LTRs of Latent Proviruses in Primary Cells.
We were able to obtain sufficient numbers of Th17 cells from a
healthy male donor (donor 7) to measure the occupancy of ESR-
1 on the HIV-1 LTR by sensitive ChIP assays based on ion
torrent sequencing (Fig. 3) (22). LTR-specific primer sets each
Fig. 2. Synergism and antagonism of SERMs and LRAs in the QUECEL (Th17) primary cell model. (A) HIV-1 reporter virus. (B) Experimental design. (C) Assay of
ESR-1 agonists. Cells were stimulated overnight through the TCR or by 500 nM SAHA, 10 ng/mL TNF-α, or 10 ng/mL IL-15. The addition of 300 pg/mL β-estradiol
or 1 nM stilbesterol greatly reduced the reactivation of latent HIV-1 by each of these LRAs. Symbols indicate separate experiments using various donors: D7
(female; squares), D5 (male; circles), and D4 (male; triangles). Reactivation was measured by flow cytometry scoring for Nef+, pSer175+ cells. (D) Antagonists of
ESR-1 are either additive or synergistic when combined with LRAs. Cells were activated as described above in the absence or presence of SERMs (ICI and TMX)
and the NCOA1/3 inhibitor gossypol. (E) Table showing the average fraction of Nef+, pSer175+ cells following treatment with LRAs and ESR-1 agonists using
the data in A and BLISS scores (bold). Table cells are color-coded based on the degree of antagonism (red, BLISS >1). (F) Table showing the average fraction of
Nef+, pSer175+ cells following treatment with LRAs and ESR-1 antagonists, using the data in B. BLISS scores are indicated in bold. Table cells are color-coded
based on the degree of synergism (green, BLISS <1), additivity (white, BLISS = 1), or antagonism (red, BLISS >1).
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carrying one primer containing unique viral sequences in Gag or
Nef that are adjacent to the 5′ or 3′ LTR and a second primer
within the LTR were used to distinguish between the two LTRs
(Fig. 3A) (22). ChIP assays were performed on quiescent cells,
and cells were stimulated for 0.5 or 16 h via the TCR in the
presence or absence of ICI or β-estradiol.
The distribution of RNA polymerase II (RNAP II) on the
HIV-1 provirus was determined using antibodies that detect the
pSer5 and pSer2 phosphorylated forms of RNAP II (Fig. 3 B and
C) (22). The combination of these antibodies allow us to dis-
tinguish between RNAP II paused proximally to the HIV-
1 promoter (pSer-5) and elongating RNAP II transcription
complexes that have been activated by Tat/P-TEFb (pSer-2 plus
pSer-5) (22). In the quiescent cells, minimal RNAP II was de-
tected by the pSer5 antibody at the 5′ LTR and 3′ LTRs due to
the highly restricted transcription in latently infected cells (Fig.
3B). This is also consistent with our previous observation that
only hypophosphorylated RNAP II accumulates at the 5′ LTR of
latently infected cells (36). Stimulation of the cells through the
TCR resulted in a large accumulation of promoter-proximal
RNAP II (pSer5) at both 30 min and 16 h. Essentially all the
RNAP II (pSer 5) is associated with the 5′ LTR after 30-min
induction by TCR. However, after 16 h of induction, there is
significant accumulation of RNAP II at the downstream LTR, in
agreement with our previous observation that there is a 4-h lag
before the induction of Tat from latent proviruses (24). Con-
sistent with these results, RNAP II (pSer2) accumulates at high
levels on the 3′ LTR only after 16 h of TCR induction (Fig. 3C).
ICI is able to increase RNAP II (pSer5) accumulation in la-
tently infected cells, which is indicative of its impact in reversing
blocks imposed by ESR-1 (Fig. 3B). ICI also significantly in-
creases the levels of RNAP II (pSer5 and pSer2) at the 3′ LTR,
which is a measure of enhanced transcription (Fig. 3 B and C), at
16 h after the initial TCR induction. The ChIP assay also con-
firmed direct transcriptional repression imposed by β-estradiol,
which leads to a dramatic reduction of RNAP II (pSer5) at the 5′
and 3′ LTRs and reduction of RNAP II (pSer2) at the 3′ LTR
after stimulation by TCR (Fig. 3 B and C).
Using the same samples, the distribution of ESR-1 (Fig. 3D)
and β-catenin (Fig. 3E), which has been reported to be part of a
corepressor complex recruited by ESR-1 in activated T cells, (17)
was measured. Importantly, the quiescent cells accumulate ESR-
1 at both LTRs, and ESR-1 levels rise in the presence of added
β-estradiol, consistent with the role of ESR-1 as a repressor of
HIV-1 transcription. ESR-1 levels fall dramatically in the pres-
ence of ICI or after activation via the TCR. β-Catenin levels
fluctuate in parallel with ESR-1 levels, and both ESR-1 and
β-catenin levels are inversely correlated with RNAP II levels
(Fig. 3 D and E).
As a control for the impact of these drugs on total cellular
ESR-1 levels, CD4 T cells from one male and one female donor
were treated similarly as in the ChIP assay. Nuclear extracts were
collected, and ESR-1 expression levels were detected via West-
ern blot (SI Appendix, Fig. S6C). Both donors had similar levels
of ESR-1 protein, which remained relatively constant under all
conditions, although there was a general increase in ESR-1 levels
at 16 h (SI Appendix, Fig. S6D).
Women Have Reduced Inducible RNA Reservoirs Compared with Men.
The preceding molecular experiments demonstrate a direct role
for ESR-1 in the silencing of HIV-1. These observations led us to
hypothesize that there would be sex-specific differences in both
the size of the inducible HIV-1 reservoir and the response to
LRAs in the presence and absence of hormones and SERMs. We
obtained leukapheresis samples from six women and six men from
a cohort of well-matched reproductive-aged females and males
that has been extensively characterized as part of a study of gender
differences. As shown in Table 1, the men and women in this
group, as in the larger cohort, were matched by age, CD4 nadir,
pretreatment viral load, time of suppression, and duration of in-
fection. None of the women used hormonal contraception.
To address difficulties in quantitation of the inducible HIV-
1 reservoir, we developed an NGS-based protocol called
“EDITS” (envelope detection by induced transcription-based
sequencing) to measure inducible cell-associated HIV-1 RNA
(Fig. 4). Briefly, 1.25 × 106 resting memory cells from the virally
suppressed (<20 copies/mL) HIV-1–infected donors were in-
duced by a range of LRAs and by engagement of the TCR.
mRNA was isolated from the cells, and cDNA corresponding to
the multiply spliced env mRNA was amplified by nested PCR
using a forward primer upstream of the major splice donor site
combined with a reverse primer permitting identification of
splice junctions spanning diverse regions of the genome (Fig. 4A)
(37, 38). The samples treated under the various conditions and
from different patients were bar-coded, pooled, and sequenced
simultaneously. This approach is efficient with respect to time
and sequencing costs and allows accurate comparisons since in-
put cDNA levels are effectively normalized.
Because latently infected cells carry only one provirus on av-
erage (39), the frequency of RNA reads obtained by sequencing
is proportional to the number of inducible cells in each of the
wells. The readouts from the EDITS assay therefore can be used
Fig. 3. ChIP assay demonstrating repression of HIV-1 transcription by ESR-1.
Latently infected Th17 cells were activated through the TCR by CD3/CD28-
coated magnetic beads for either 0.5 or 16 h in the presence or absence of
1 μM ICI or 300 pg/mL β-estradiol. (A) Location of primers used to detect
protein interactions at the 5′ and 3′ LTRs of the HIV-1 provirus. (B) RNAP II
pSer5. (C) RNAP II pSer 2. (D) ESR-1. (E) β-catenin.
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to estimate the total number of inducible cells in a sample by
comparing sequencing reads to a calibration curve produced by
sorting specific numbers of TCR-activated primary memory cells
infected with a replication-competent HIV-1 virus carrying a GFP
reporter (Fig. 4B). The accuracy of the EDITS measurements was
verified for three donors by using limiting dilution assays (SI Ap-
pendix, Fig. S7 A and B) (40). There was reasonable agreement
between the estimates obtained by maximum likelihood estimates
of the diluted samples and quantitation by the EDITS method;
however, the maximum likelihood estimates had very large con-
fidence limits that obscured the differences between samples
measured by the EDITS results, which had SDs of <5%.
As expected there was no correlation between estimates of
HIV proviral DNA loads obtained by qPCR and droplet digital
PCR (ddPCR) and the EDITS assay, due to the presence of
defective genomes within the peripheral HIV reservoir which
typically resulted in a 10-fold excess of genomes (Fig. 4C).
When the inducible RNA reservoir size as measured by the
EDITS assay was compared between the women and men, lower
levels of inducible RNA were reproducibly found in cells derived
from women, and even within this comparatively small sample
the accuracy of the EDITS analysis resulted in a highly statisti-
cally significant value (P = 0.005) (Fig. 5). The data shown in Fig.
5 include data from six male and six female donors obtained
using two sequencing platforms with three technical replicates
per condition (i.e., biological and technical replicates). The data
were analyzed using linear mixed effects models suitable for
analysis of RNA-sequencing (RNA-seq)–based data, with donors
as random variables and sequencing platforms as blocking vari-
ables. In SI Appendix, Fig. S8, the TCR induction data used to
generate Fig. 5 are presented for each individual patient. This
illustrates the high reproducibility of the EDITS assay for the
biological and technical replicates as well as the minimal back-
ground signals seen before induction by LRAs.
Impact of SERMs and β-Estradiol on the Reversal of HIV-1 Latency ex
Vivo. The EDITS assay was also used to study the impact of
β-estradiol on proviral reactivation and possible synergistic or
additive effects of a SERM and an LRA, in this case, ICI and
SAHA (Fig. 5). These compounds also were tested in the
QUECEL (Th17) assay and Jurkat (2D10) models. Data from
both models show a high degree of correlation with each other
(R2 = 0.923) and the EDITS assay (R2 = 0.935) (SI Appendix,
Fig. S7 C and D), indicating that they share a common mecha-
nism in each system.
Gender-Specific Differences. These experiments revealed striking
differences in the responsiveness of females compared with
males to ESR-1 agonists and antagonists (Fig. 5 and SI Appendix,
Fig. S8). In women, the addition of 300 pg/mL β-estradiol, which
is a level comparable to peak levels in healthy cycling women
(the peak level noted in plasma from the leukapheresis samples
was 395 pg/mL), completely abolished responses to TCR stim-
ulation (mean 97.7%). By contrast, in men, β-estradiol was still a
potent inhibitor of reactivation but reduced TCR stimulation
levels by only 47.5% (P = 0.0013 vs. women). ICI was a poor
inducer in women and was inactive in men. When combined with
SAHA, ICI showed synergistic induction in women (mean in-
crease 17.9%) but did not substantially increase proviral reac-
tivation in men (mean increase 2.9%, P < 0.0001). This pattern
of enhanced responses to β-estradiol and SERMs is evident in
each of the women compared with each of the men.
To confirm the synergistic effects of SERMs and SAHA in
women, but not in men, reciprocal titrations of TMX and SAHA
were performed using three representative donors (SI Appendix,
Fig. S9 A and B). The data show the expected EC50 values for
each drug and confirm the synergistic interactions between
SAHA and TMX in women. Three distinct SERMs (TMX,
raloxifene, and ICI), showed similar synergistic behavior when
combined with SAHA in women, but not in men (SI Appendix,
Fig. S9C).
To further verify the role of the estrogen receptor pathway in
postmenopausal women, we examined cryopreserved PBMCs
from four women on fully suppressive ART followed as part of a
longitudinal observational cohort (A5321). These samples were
Table 1. Demographics and clinical parameters of study subjects
Parameter Women Men P value
Age, y (range) 44 (30–48) 36.5 (32–54) 0.6
CD4 nadir in cells/μL (range) 213.5 (76–661) 210 (129–480) 0.9
Log maximum pretreatment viral load in
copies/mL (range)
4.63 (4.05–5.41) 5.19 (2.85–5.70) 0.5
Duration of viral suppression, mo (range) 37 (19–131) 37 (24–98) 0.9
Duration of HIV-1 infection, y (range) 11.5 (5–16) 8 (5–16) 0.5
For each variable the median and range of values are shown. P values are shown for the comparison of men
and women using Mann–Whitney U nonparametric statistics. The use of hormonal contraception was an
exclusion criterion for the women.
Fig. 4. EDITS assay for measuring RNA induction in patient cells. (A) Loca-
tion of primers used to detect HIV-1 Env mRNA. (B) Quantitative measure-
ment of inducible cells using EDITS. The calibration curve was produced by
sorting specific numbers of activated primary memory cells infected with a
replication-competent HIV-1NL4-3 GFP-reporter virus. TCR-induced cells from
11 patients are plotted, showing the range of values obtained by EDITS. Blue
diamonds are males, and red diamonds are females. (C) Proviral DNA viral
loads do not correlate with EDITS reservoir measurements. Proviral DNA
levels were determined using either a qPCR assay (red circles) or a digital
droplet DNA assay (black squares), which was more sensitive and able to
detect proviral DNA in all of the samples.
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stimulated ex vivo and analyzed by the EDITS assay, as described
above (SI Appendix, Fig. S10), except that concanavalin A was
used in place of TCR stimulation as the maximal stimulation
condition. These results demonstrated that postmenopausal
women retained the strong susceptibility to estrogen-mediated
repression of transcription. Although these participants also
showed an increase in HIV-1 RNA production after ex vivo
treatment with TMX, the levels of HIV-1 RNA production in-
duced by SAHA were similar to the levels induced by the com-
bination of TMX and SAHA, as was previously observed in men.
Discussion
ESR-1 Is a Key Regulator of HIV-1 Latency. The need to develop
novel therapeutics to attack the latently infected population
during HIV infection and prevent a rebound of virus after ter-
mination of suppressive ART is a widely recognized goal of ef-
forts at HIV-1 cure (11, 12). Clinical trials testing candidate
LRAs have demonstrated transient increases in intracellular
HIV-1 RNA after treatment of study participants with a variety
of HDACis [SAHA (41, 42), panobinostat (43), romidepsin (44,
45)] and the phosphatase and tensin homolog (PTEN) inhibitor,
disulfiram (46). However, despite this proof of concept, all these
agents are highly inefficient ex vivo compared with the maximal
induction observed with TCR stimulation. Furthermore, even
after maximal activation of T cells ex vivo, a significant pro-
portion of proviruses remain uninduced (14), highlighting the
inadequacy of current strategies.
To identify host factors controlling HIV-1 latency in an unbiased
manner, we performed shRNA library screens for repressors of
HIV-1 transcription using a sequencing strategy as a readout (47,
48). ESR-1 was reproducibly found among highest the hits in
multiple screens. Subsequent bioinformatic analyses demonstrated
that ESR-1 is a key cellular factor for regulating HIV-1 latency.
The importance of ESR-1 in regulating HIV-1 latency has
been largely overlooked. Female sex hormones and their re-
ceptors are likely to have direct effects on HIV-1 replication at
the molecular level (17). However, previous mechanistic studies
have led to seemingly contradictory results, with low levels of
estrogen reported to activate the HIV-1 LTR (49) while higher
levels are inhibitory (17, 50). None of these studies addressed the
role of estrogen and ESR-1 in maintaining latency in quiescent
T cells, which have a very different physiology from activated and
transformed cells.
Using two complementary models of HIV-1 latency, Jurkat
T cells and QUECEL (Th17 cells), and subsequently by the di-
rect assessment of effects in primary samples from a unique
cohort of chronically infected patients on treatment using the
EDITS assay, we showed that agonists of ESR-1, including
β-estradiol, are potent repressors of HIV-1 reactivation. By
contrast, the SERMs TMX, raloxifene, and ICI partially reverse
latency and sensitize the provirus for reactivation. The impacts of
the SERMs and hormones in each of these systems are highly
correlated, and this strongly suggests that ESR-1 acts directly on
HIV transcription, independently of the cellular background.
Mechanistically, we showed in primary T cells that latency re-
versal by down-regulation of ESR-1 is a result of the recruitment
of repressor complexes to the HIV-1 LTR by ESR-1. ChIP assays
showed that latent proviruses rapidly accumulate RNAP II at the
5′ LTR after TCR induction, but little RNAP II reaches the 3′
LTR until Tat accumulates in the cells (22, 24). The SERM ICI
enhances RNAP II recruitment at the HIV 5′ LTR and elongates
RNAP reaching the 3′ LTR, while β-estradiol strongly inhibits
TCR-mediated reactivation. Consistent with this transcriptional
pattern, ESR-1 levels at the LTR fluctuate as expected upon
pharmacologic modulation (i.e., increase with SERMs and de-
crease with hormone). Interestingly, β-catenin, which has been
associated with a corepressor complex recruited by ESR-1 (17),
fluctuates in parallel with ESR-1.
There are no obvious ESR-1–binding sites on the HIV-1 LTR,
suggesting that the recruitment may be indirect (51). A potential
mediator of ESR-1 recruitment is Sp1, which binds constitutively
to three sites in the HIV-1 core promoter (52). Interactions
between Sp1 and ESR-1 and ESR-2 have been reported to re-
cruit corepressor complexes at a number of genetic loci (53, 54).
Alternatively, TCF-4 may mediate ESR-1 recruitment to the
HIV-1 LTR (17, 55). However, neither TCF-4 nor β-catenin
appeared as reproducible hits in the shRNA screens. Although
the recruitment mechanism remains to be clarified, our work
clearly demonstrates that the recruitment of ESR-1 directly
suppresses HIV-1 transcription in quiescent cells and is re-
quired to maintain HIV-1 latency.
Women Have Lower Inducible HIV-1 RNA Reservoirs than Men.
Women represent half of the 36.7 million people currently liv-
ing with HIV-1 [Joint United Nations Programme on HIV/AIDS
(UNAIDS), 2017, www.unaids.org/en/resources/documents/2017/
2017_data_bank], and young women 15–24 y old represent 30% of
new HIV-1 infections in key regions, a rate almost twice as high as
young men. Numerous studies have shown considerable sex dif-
ferences in the manifestations of HIV-1 (18), although it is unclear
whether these are due to intrinsic differences in immunological
responses, differential susceptibility to the virus, behavioral mod-
ulators, effects due to hormonal differences, or a combination of
all these factors (56–58).
The EDITS assay was used to measure both the total inducible
RNA reservoir size and the impact of SERMs and hormone on
HIV-1 latency reversal using a well-matched cohort of men and
women composed of participants in the University of California,
San Francisco (UCSF) SCOPE cohort and patients enrolled in
the San Francisco General Hospital Ward 86 HIV clinic. Fe-
males were excluded from this study if they were on hormonal
contraceptive therapy to eliminate the possible in vivo effects of
contraception on the HIV reservoir.
Fig. 5. EDITS estimate of the inducible RNA reservoir size in females and
males. EDITS assays were performed on unstimulated cells or cells activated
by TCR stimulation (maximal activation) in the presence and absence of
300 pg/mL β-estradiol, 1 μM ICI, 500 nM SAHA, or a combination of ICI and
SAHA. For each donor, the EDITS assays were performed on three separate
occasions using separate aliquots (biological replicates). Libraries were pre-
pared from the isolated RNAs and were sequenced in two separate runs
(technical replicates). Solid circles: PGM sequencer. Open symbols: S5 se-
quencer. Males respond statistically better than females to TCR stimulation
(P value = 0.005), indicating a larger inducible reservoir size.
Das et al. PNAS | vol. 115 | no. 33 | E7801
M
IC
RO
BI
O
LO
G
Y
The reservoir size was estimated by comparing the levels of
induced RNA following TCR stimulation with a standard curve
created using individually sorted productively infected cells.
Treating the same cells with LRAs leads to partial reactivation of
the population, and this provides a measure of the potency of
these drugs. Consistent with the EDITS results, using the related
Tat/rev-induced limiting-dilution assay (TILDA) (59) from a
partially overlapping subset of 22 men and women from the same
cohort, women showed an approximately twofold lower level of
inducible HIV-1 RNA when controlled for HIV-1 proviral res-
ervoir size. However, the confidence limits of the TILDA, which
is a limiting-dilution assay, are considerably higher than those of
the EDITS assay.
Sequencing-based assays, such as EDITS, provide an accurate
and quantitative alternative for measuring levels of inducible
viral RNA (60, 61). Although these assays do not directly mea-
sure the number of cells capable of producing infectious virions
(because some of the signals may arise from defective proviruses
in the samples), they can be regarded a providing an upper limit
for the inducible reservoir size. It was originally suggested that
less than 10% of cells producing viral RNA gave rise to in-
fectious virus (62), but a recent highly sensitive quantitative viral
outgrowth assay (Q-VOA) suggests that between 20–70% of the
cells able to produce HIV-1 RNA produce infectious virus par-
ticles (63).
The EDITS data also demonstrate significant sex differences in
the response to ex vivo exposure to hormones and SERMs. Re-
pression of HIV-1 transcription by β-estradiol is much more pro-
nounced in women than in men. Similarly, women are more
responsive than men to HIV-1 induction by SERMs. Intrinsic dif-
ferences in the levels of estrogen receptors and their cofactors in
T cells conditioned by distinct in vivo hormonal environments in
men and women may account for these differential responses to
hormones and SERMs. Further work is needed to determine
whether these pathways are similarly operative in vivo where phar-
macologic exposure to antagonists or hormones could be sustained.
Although the impact of drugs on HIV latency generally cor-
related extremely well between the patient samples, these sex
differences were not obvious in our model systems. Jurkat T cells
and most of our healthy donors are male, so we may not have
had sufficient statistical power to distinguish between the gen-
ders. However, it may also be possible that some subtle features
of the regulation are lost in the transformed cells and after the
extensive manipulations required for the QUECEL model,
which has higher basal activation and is more responsive to
LRAs than are patient cells.
It remains to be determined whether the reduced reservoir
seen in women is a direct consequence of the profound inhibition
of HIV-1 reactivation and replication by β-estradiol, whether
better immunological control by women leads to a reduction in
the reservoir size, or whether a combination of these factors is
at play.
Impact of Sex on HIV-1 Eradication Strategies. Our results suggest
that concurrent exposure to estrogen may limit the efficacy of
LRAs. There has been a consistent underrepresentation of
women in trials relevant to cure (64). Given the small size and
exploratory nature of clinical trials of cure to date, the inclusion
of women in small clinical trials may lead to skewed results if
hormone exposure is not considered. Furthermore, since reac-
tivation of the HIV-1 reservoir is potently inhibited by estrogen,
studies of the impact of hormonal contraception on reservoir
establishment and its long-term maintenance should be un-
dertaken. Similarly, it will be important to investigate whether
hormonal fluctuations during the menstrual cycle have an impact
on residual viremia in well-suppressed patients.
Hormone-modulating therapy with various SERMs, including
ICI, TMX, and raloxifene, is routinely used in the context of
breast cancer treatment (65–72). Repurposing these extensively
used drugs suggests a practical route to exploit the potentially
synergistic activities of SERMs and other latency-reversal clas-
ses, such as HDACi, for HIV eradication efforts. While in vitro
and ex vivo studies demonstrate an important role of hormones in
latency reversal, the complexity of the system obligates further
clinical investigation. The work detailed here has provided the
scientific underpinning for a preliminary trial of the effects of
TMX and vorinostat on the HIV reservoir among postmenopausal
HIV-infected women, AIDS Clinical Trials Group (ACTG) study
A5366, Selective Estrogen Receptor Modulators to Enhance the
Efficacy of Viral Reactivation with Histone Deacetylase Inhibitors
(ClinicalTrials.gov Identifier: NCT03382834). Further investiga-
tions to elucidate sex differences in latency reversal and HIV
persistence are mandatory to extend the benefits of the HIV cure
effort to all men and women impacted by the global epidemic.
Materials and Methods
Cell Lines and Tissue-Culture Conditions. Latently infected Jurkat 2D10 cells
were used for the shRNA screens and initial characterization of SERMs (21). To
minimize exposure to estrogen and estrogen mimics, all cells used in these
experiments were maintained in phenol red-free HyClone RPMI medium
with L-glutamine, 10% charcoal-stripped FBS, 100 IU/mL penicillin, and
100 μg/mL streptomycin in 5% CO2 at 37 °C. Levels of β-estradiol in all media
were confirmed by ELISAs (SI Appendix, Fig. S6).
Cells were pretreated with estrogen receptor agonists or antagonists for
2 h before additional stimuli. Estrogen receptor agonistswere 300 pg/mL β-estradiol
(E2758-1G; Sigma) and 1 nM stilbesterol (ab142421; Abcam). The estrogen receptor
antagonists ICI (10-471; R&D Systems), tamoxifen citrate (09-991-00; R&D Systems),
and raloxifene hydrochloride (22-805-0; R&D Systems) were used at 1 μM for
QUECEL experiments and at 2.5 μM for the Jurkat T cell experiments.
QUECEL (Th17) Cell Model for HIV-1 Latency. Polarized Th17 cells were gen-
erated from naive CD4+ T cells that were negatively isolated from PBMCs using
the Human Naive CD4+ T Cell Enrichment Kit (19155RF; STEMCELL Technolo-
gies) as described (20). Afterward, cells were infected with VSV-G pseudotyped
HIV-1 Nef+ virus, which expresses CD8a-d2EGFP. HIV-1–infected cells were
purified using the anti-CD8a selection kit (18953; STEMCELL Technologies).
Cells were then forced into quiescence with culture in medium supplemented
with 15 IU/mL IL-2, 12.5 ng/mL IL-23, 10 ng/mL TGF-β, 50 ng/mL IL-10, and
50 ng/mL IL-8. Entry of the cells into quiescence was confirmed using flow
assays showing the loss of pS175 CDK9 (25) and the reduction of cyclin
D3 levels. Maximal reactivation of proviral gene expression was achieved by
incubating cells overnight with Dynabeads Human T-Activator CD3/CD28
(25 μL per 106 cells). The high reproducibility of the assay permitted us to
combine data from multiple experiments without normalization.
Flow Cytometry Analysis. Cells were analyzed using a BD LSRFortessa flow
cytometry instrument. For intracellular staining, samples were fixed in 4%
formaldehyde (Electron Microscope Sciences) for 15 min at room tempera-
ture. Cells were permeabilized and stained using an antibody mixture con-
taining AF647-HIV-1 EH1 Nef [the gift of James A. Hoxie, Perelman School of
Medicine, University of Pennsylvania, Philadelphia (73)], AF750-pSer175 CDK9
(generated by Covance for the J.K. laboratory), and TRITC-Cyclin D3 (Santa
Cruz Biotechnologies). Data were analyzed using WinList 3D version 9.
shRNA Library Screening. The human module shRNA library in a lentiviral
vector was obtained from Cellecta, Inc. For the repressor screen, latent HIV
2D10 cells were infected in parallel with each of the shRNA library modules
and were grown in puromycin selection medium for 14 d with a regular
change of fresh medium. Double-positive [d2EGFP+ (HIV-1 expression), RFP+
(shRNA vector)] cells representing the constitutively reactivated population
were grown in puromycin selection medium for 7 d before the next round of
cell sorting. Three consecutive cycles of sorting were performed. After each
step of purification, 2–5 × 106 cells were harvested, and genomic DNA was
isolated using a Qiagen Blood and DNA mini Kit. For the activator screen,
latently infected 2D10 cells were infected with the shRNA library, as above.
The day before each stage of cell sorting, the cells were stimulated with
TNF-α, and the d2GFP−, RFP+ cells were purified and genomic DNA was
isolated, as above.
Isolated genomic DNA was used as a template to amplify the barcode
sequences of shRNAs by nested PCR. Agarose gel (1%)-purified amplified
barcode sequences were then sequenced by Illumina high-throughput
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sequencers, and the sequences were deconvoluted to their target mRNA
sequences using software tools provided by Cellecta, Inc.
Robo ChIP. ChIP was performed on 106 cells per condition using our pre-
viously described Robo Chip protocol (22). Antibodies used for immuno-
precipitations included anti-RNAP II pSer5 (ab5131; Abcam), anti-RNAP II
pSer2 (ab5095; Abcam), anti–ESR-1 (SAB4300344; Sigma), and anti–β-catenin
(610154; BD Biosciences).
Study Cohort. Study participants were enrolled through the UCSF SCOPE
cohort between March 2014 and April 2015. Clinical and demographic in-
formation was collected, and reproductive health questionnaires were
completed with study staff. A subset of participants (six women and six men)
returned for leukapheresis. All subjects provided informed consent, and the
study was reviewed and approved by the UCSF institutional review board.
Additional samples from postmenopausal women were obtained through
the ACTG longitudinal study A5321 for testing ex vivo HIV-1 RNA induction in
the presence of hormones and antagonists.
RNA Induction Assay (EDITS Assay). Well-suppressed PBMCs from the patients
in the cohort were obtained by leukapheresis. CD4+ memory cells were
negatively isolated using robotic magnetic bead isolation using the EasySep
Human Memory CD4 T Cell Enrichment Kit (19157; STEMCELL Technologies).
For each determination, 1.25 × 106 cells were used. Cells were induced with
Dynabeads Human T-Activator CD3/CD28 (25 μL per 106 cells), IL-15 (50 ng/mL),
or SAHA (500 nM) overnight in the presence or absence of the indicated
SERMs and ESR-1 agonists. Total RNA was isolated using the RNeasy purifica-
tion system (74134; Qiagen) following the manufacturer’s protocol. The total
sample was eluted using 20 μL of RNase-free water. The entire sample was
used as template in a one-step RT-PCR (AB-4104A; Thermo Scientific) using the
following cycling conditions: 1 cycle at 50 °C for 15 min, 1 cycle at 95 °C for
15 min, 35 cycles of 95 °C for 15 s and 60 °C for 30 s, and 72 °C for 30 s.
Primers were designed to bind to either side of the HIV-1 Env RNA splice
junction at positions 648 and 666 (forward primer AGGGACCTGAAAGC-
GAAAG) and positions c6340 and c6359 (reverse primer CCACACAG-
GTACCCCATAAT), yielding a product of 168 bp from the spliced env mRNA.
Using these primers allowed us to detect only late spliced viral transcripts and
eliminated any potential proviral DNA amplification because of the wide
spacing of the primers on the viral genome. The primer-binding regions are
located in highly conserved regions of HIV-1 based on the Los Alamos Na-
tional Laboratory HIV-1 Database.
In addition to the priming sequence, the reverse primer has a synthetic GEX
R-AATGATACGGCGACCACC sequence placed directly after the priming re-
gion to allow further amplification using nested PCR. After cDNA synthesis
and PCR, 2 μL of the reaction was used as template for a subsequent round
of nested PCR using a high-fidelity Phusion Flash polymerase (F548; Thermo
Scientific). The amplification protocol was as follows: 1 cycle at 95 °C for 30 s,
35 cycles of 95 °C for 1 s, 62 °C for 5 s, and 72 °C for 5 s, and 1 cycle of 72 °C
for 1 min. The nested primers were designed to bind to positions 757 and
776 of HIV-1 (forward primer AAATTTTGACTAGCGGAGGC and nested GEX
reverse primer AATGATACGGCGACCACC) and were added during the first
round of PCR.
To allow for NGS, ion torrent A forward and Trp reverse adapters were
added to the nested primer sets, and a unique barcode was added in the
forward primer to allow multiplexing of samples. Samples were then pooled
and purified up using the GeneJET NGS cleanup kit (FERK0852; Thermo
Scientific) to remove residual free primers. Three hundred picograms of the
pooled sample were then sequenced using an ion torrent sequencing system
following the manufacturer’s protocol. Sequencing was performed on either
an S5 sequencer (Thermo Fisher) using a 540 chip (80 million reads) or a PGM
sequencer (Thermo Fisher) using the 318 chip (8 million reads).
Barcodes were separated by sample using the Ion Torrent Browser, and all
reads were filtered to remove short products (<80 bp); only reads that
contained the GEX reverse sequence were retained. The filtered reads were
then mapped to a synthetically spliced HXB2 sequence, and total mapped
reads were scored. The number of mapped reads was then converted into
the equivalent number of cells harboring HIV-1 per 106 cells using a standard
curve prepared from activated memory cells infected with replication-
competent HIV-1–GFP virus and then were sorted by flow cytometry into
single wells of a 96-well plate. Samples for the standard curve contained
between 1 and 300 infected cells per well and 1.25 × 106 uninfected cells.
The samples were processed, barcoded, pooled with the experimental EDITS
samples, and sequenced.
3D Digital PCR Proviral DNA Assay. DNA was isolated from memory T cells of
HIV+ donors (DNeasy Blood and Tissue Kit; Qiagen) and was quantified by
the Qubit HS dsDNA assay (Fisher Scientific). Up to 2 μg of cellular DNA was
mixed with QuantStudio 3D Digital PCR Master Mix v2 and 1× HIV-1 5′ LTR
primer/probe mix (TaqMan Expression Assay; Life Technologies) and spread
evenly onto two separate 20-K v2 chips with a QuantStudio 3D Digital PCR
chip loader. Chips were then filled with immersion fluid and sealed. HIV 5′
LTR primers in this assay amplify a 128-bp product that maps to nucleotide
positions 588–716 of the HXB2 genome. Cellular DNA from uninfected do-
nors served as the negative control. Loaded chips were thermally cycled on a
ProFlex 2× flat PCR system (Thermo Fisher Scientific) using the manufac-
turer’s suggested conditions (96 °C for 10 min, 39 cycles of 60 °C for 2 min
and 98 °C for 30 s, and 60 °C for 2 min) and were held at 10 °C. Cycled chips
were read with a QuantStudio 3D Digital PCR Instrument and were analyzed
using QuantStudio 3D AnalysisSuite Software. Thresholds for positive wells
on all chips were based on nonspecific fluorescence from a negative control
DNA chip. Results given in HIV copies per microliter were then translated to
HIV copies per 106 cells. The ddPCR determinations correlated nicely with
qPCR performed on parallel samples using standard methods but were more
sensitive and therefore were able to quantify proviral DNA in various sam-
ples where it was undetectable by qPCR.
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